Health
STRENGTH Trial Questions CV Benefit of High-Dose Omega-3s – Medscape
Questions about the cardiovascular benefit of omega-3 fatty acids and the high-dose eicosapentaenoic acid (EPA) product, icosapent ethyl (Vascepa, Amarin), have resurfaced with the presentation and publication of the STRENGTH trial using a combined high-dose omega-3 fatty acid product.
The STRENGTH trial showed no benefit on cardiovascular event rates of a high-dose combination of EPA and docosahexaenoic acid (DHA) in a new branded product (Epanova, AstraZeneca).
It was announced in January that…
-
Noosa News22 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News21 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation